Takeda ALK inhibitor Alunbrig (brigatinib) stage 3 clinical trial shows good long-term efficacy

Takeda(http:// announcedthat its next-generation ALK inhibitor, Alunbrig (brigatinib), had shown good long-term efficacy in the treatment of alK-positive non-small cell lung cancer (NSCLC) patients in phase 3 clinicaltrial(http://About Alunbrig
Alunbrig was able to reduce the risk of disease progression or death by 57% compared to common generation ALK inhibitorsIn patients with brain metastasis, Alunbrig was able to reduce the risk of progression or death by 76%Alunbrig is the next generation of tyrosine kinase inhibitors (TKI) developed by Takeda, which are designed to target and inhibit ALK fusion proteinsIn April 2017, it received accelerated approval from theFDA(http://to treat PATIENTs with ALK-positive metastatic NSCLCThese patients continued to progress after receiving crizotinib treatmentAbout ALTA-1L 275 PATIENTS WITH ADVANCED OR METASTATIC NSCLC WHO WERE TREATED WITH ALUNBRIG OR CRIZOTINIB IN AN OPEN LABEL CALLED ALTA-1L, A RANDOMIZED MULTICENTER PHASE 3 CLINICAL TRIAL The patient was not previously treated with ALK inhibitors 　　The results showed that the non-progressive life span (PFS) in patients in the Alunbrig group was 29.4 months, compared with 9.2 months in the active control group For patients with brain metastasis, PFS in the Alunbrig group was 24 months and the active control group was 5.6 months Alunbrig also significantly improves the quality of life of patients